Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo patch Clear all
Completed Phase 3 Interventional

Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

NCT00352625
View directory record Official record
Conditions
Tendonitis, Bursitis
Interventions
Ketoprofen Topical Patch 20%
Drug
Lead sponsor
Alkemira SA
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

NCT00699556
View directory record Official record
Conditions
Alcohol Drinking
Interventions
21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, placebo nasal spray
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2Phase 3 Interventional

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

NCT00264732
View directory record Official record
Conditions
Uterine Cervical Dysplasia
Interventions
Amolimogene, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
13 Years to 25 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals

NCT00308763
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine Patch, Sustained Release Bupropion
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 45 Years
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

NCT00646867
View directory record Official record
Conditions
Contact Dermatitis
Interventions
Tetrix, Placebo
Device
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 18, 2026, 11:12 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Auriculotherapy - Pain Management of Aspiration Abortion

NCT03896022
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Acupressure with Beads, Acupuncture with Needles, Placebo Adhesive Disks
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

Telephone Counseling and the Distribution of Nicotine Patches to Smokers

NCT00851357
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Patch, Telephone Counseling, Placebo, Self-Help Materials
Drug · Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Not applicable Interventional Results available

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

NCT00756275
View directory record Official record
Conditions
Smoking Cessation, Nicotine Dependence
Interventions
Nicotine Replacement Treatment (NRT), varenicline, Behavioral counseling for smoking cessation
Drug · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 75 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 18, 2026, 11:12 AM EDT
Active, not recruiting Phase 3 Interventional

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919
View directory record Official record
Conditions
Allergy, Peanut Allergy
Interventions
DBV712 250 mcg, Placebo
Combination Product
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Not listed Phase 2 Interventional

Evaluating Efficacy of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty

NCT04242407
View directory record Official record
Conditions
Pain, Postoperative
Interventions
DMTS, Placebo
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Bellaire, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

NCT00684177
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Ointment, 1%, Placebo ointment
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Months and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
32
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Study of ALTO-101 in Patients With Schizophrenia

NCT06502964
View directory record Official record
Conditions
Schizophrenia, Cognitive Impairment
Interventions
ALTO-101, ALTO-101 Transdermal Delivery System, Placebo, Placebo Transdermal Delivery System
Drug · Device
Lead sponsor
Alto Neuroscience
Industry
Eligibility
21 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Garden Grove, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting Phase 2Phase 3 Interventional

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

NCT06947928
View directory record Official record
Conditions
Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
IFx-Hu2.0, Placebo, Pembrolizumab
Drug
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail

NCT01400594
View directory record Official record
Conditions
Onychomycosis
Interventions
HTU-520 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 18, 2026, 11:12 AM EDT
Not listed Phase 2 Interventional

Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

NCT01560754
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine transdermal patch
Drug
Lead sponsor
James BOYD MD
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Sunnyvale, California • Honolulu, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Oct 18, 2026, 11:12 AM EDT
Not yet recruiting Not applicable Interventional

NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty

NCT07439666
View directory record Official record
Conditions
Total Knee Arthroplasty Postoperative Pain, Opioid Reduction After TKA
Interventions
NEUROCUPLE™ Patch, Sham patch, Enhanced Recovery After Surgery (ERAS) Standard of Care
Device · Other
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee

NCT00108810
View directory record Official record
Conditions
Pain, Osteoarthritis, Knee
Interventions
Transdermal Ketoprofen Patch with CHADD, Placebo transdermal patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Buena Park, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Results available

FS-67 in the Treatment of Pediatric Patients With Ankle Sprain

NCT01037816
View directory record Official record
Conditions
Ankle Sprain
Interventions
FS-67 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 18, 2026, 11:12 AM EDT
Recruiting Phase 4 Interventional

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277
View directory record Official record
Conditions
Depression, Psychosis, Anhedonia
Interventions
Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Results available

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Selegiline Patch for Treatment of Nicotine Dependence

NCT01330030
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Selegiline, matching placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 18, 2026, 11:12 AM EDT
Completed Early Phase 1 Interventional Results available

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

NCT02849639
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Placebo, Medication Therapy Management (MTM), Scopolamine patch
Other · Drug
Lead sponsor
Daniela Moga
Other
Eligibility
65 Years to 101 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 18, 2026, 11:12 AM EDT